

A NEW SYNTHESIS OF 2',3'-DIDEOXYNUCLEOSIDES
FOR AIDS CHEMOTHERAPY


Vittorio Farina*^{a)} and Daniel A. Benigni

Pharmaceutical Research and Development Division
Chemical Process Development Department
Bristol-Myers Company
Syracuse, New York 13221-4755


SUMMARY: Dideoxynucleosides were prepared in high optical purity from L-glutamic acid. The condensation reactions between activated 2,3-dideoxypentofuranoses and silylated purines or pyrimidines afforded separable β/α mixtures of dideoxynucleosides.

2',3'-Dideoxynucleosides have found utility mainly as reagents for DNA sequencing¹, and consequently are commercially available in only small amounts at very high prices². The recent discovery³ that some dideoxynucleosides selectively inhibit *in vitro* the infectivity and cytopathic effect of the HTLV-III (HIV) virus has sparked renewed interest in this class of compounds, and dideoxycytidine, **1**, is now being clinically evaluated as treatment against Acquired Immune Deficiency Syndrome (AIDS). A general and economically attractive synthesis of dideoxynucleosides has therefore become an important goal.


2',3'-Dideoxynucleosides are typically synthesized from 2'-deoxynucleosides *via* Barton-type deoxygenation reactions⁴, or from intact nucleosides by multistep routes involving deoxygenation reactions to 2',3'-unsaturated dideoxynucleosides⁵, which are then hydrogenated. Approaches through ketonucleosides⁶ and a photoreductive process⁷ have also been described.



1



2




3

We envisioned producing dideoxycytidine (ddC), **1**, dideoxyadenosine (ddA), **2**, and dideoxyinosine (ddI), **3**, from a stereochemically less complex, and much cheaper, precursor, *i.e.* L-glutamic acid (Scheme I).

The known, stereospecific deamination-lactonization reaction, followed by standard manipulations⁸, gave lactone **4**. Selective reduction⁹ with disiamylborane followed by oxidative hydrolysis and acetylation gave a good yield of acetate **5** as a mixture of anomers¹⁰.

Scheme I




Reagents: (a) disiamylborane, THF, then H_2O_2 , 50°C ; 94% (b) Ac_2O , pyridine, RT; 92% (c) Me_3SiBr , CH_2Cl_2 , 0°C , then bis-silylcytosine, $-78^\circ\text{C} \rightarrow \text{RT}$; 44% yield for **7** after chromatography; (d) NH_3/MeOH quant.

Treatment with trimethylsilylbromide¹¹ cleanly afforded a mixture of anomeric bromides¹² **6**. Addition of silylated cytosine to this solution gave a separable mixture¹³ of protected ddC and its α anomer in a 1:1 ratio¹⁴. Standard deprotection afforded ddC¹⁵.

A similar approach (Scheme II) was successful for purine nucleosides. The coupling reaction was carried out at room temperature in order to minimize formation of a side-product, presumably the N-3 alkylation product¹⁶ 11.

Scheme II



Reagents: (a) TMSBr , 0°C ; then bis-silyladenine, RT; 63% yield for 2 + 10 (b) NH_3 , MeOH, RT, quant. yield for 2 + 12 (c) adenosine deaminase, H_2O ; 33% yield for 3 after crystallization.

Dideoxyinosine, another potentially useful antiviral agent, was prepared by subjecting the mixture of 2 and 10 to a solution of the enzyme adenosine deaminase¹⁷, which quantitatively deaminated the β -anomer, leaving the α unreacted. Consequently ddI, 3, was obtained by direct crystallization of the reaction crude from methanol¹⁸.

The methodology described in this letter should make a variety of 2',3'-dideoxynucleosides easily available at very low cost.

REFERENCES AND NOTES:

- a) Present address: Pharmaceutical Research and Development Division, Bristol-Myers Company, 5 Research Parkway, Wallingford, CT 06492-7660
1. F. Sanger, S. Nicklen, A.R. Coulson Proc.Natl.Acad.Sci.USA, 1977, 74, 5463.
 2. For example, Aldrich Chemical Company sells 2',3'-dideoxycytidine at \$42.00/100 mg.
 3. H. Mitsuya, S. Broder Proc.Natl.Acad.Sci. USA, 1986, 83, 1911.
 4. See, for example: E.J. Prisbe, J.C. Martin Synth.Comm., 1985, 15, 401.
 5. See, for example: (a) J.P. Horwitz, J. Chua, M. Noel, J.T. Donatti J.Org.Chem., 1967, 32, 817 (b) K.E. Pfitzner, J.G. Moffatt J.Org.Chem., 1964, 29, 1508. (c) M.J. Robins, F. Hansske, N.H. Low, J.I. Park Tetrahedron Lett., 1984, 25, 367 and references therein.
 6. J. Thiem, D. Rasch Nucleosides & Nucleotides, 1985, 4, 487.
 7. I. Saito, H. Ikehira, R. Kasatani, M. Watanabe, T. Matsuura J.Am. Chem.Soc., 1986, 108, 3115.
 8. M. Taniguchi, K. Koga, S. Yamada Tetrahedron, 1974, 30, 3547.
 9. P. Kohn, R.H. Samaritano, L.M. Lerner J. Am. Chem. Soc., 1964, 86, 1457. We thank Dr. D.G. Walker of this department for suggesting the use of the reagent.
 10. All new compounds gave satisfactory spectral and analytical data. The α/β ratio for 5 was 55:45 and was assigned on the basis of NMR considerations. See: K.J. Stone, R.D. Little J.Am.Chem.Soc., 1985, 107, 2495.
 11. J.W. Gillard, M. Israel Tetrahedron Lett., 1981, 22, 513
 12. Use of 1.2 eq. of TMSBr was needed to achieve >90% conversion. The anomeric protons in the NMR (CDCl_3) at δ 6.80; 6.70 ($\alpha/\beta \sim 60:40$) were diagnostic. These anomeric bromides were too unstable for isolation.
 13. Separation was effected by preparative reverse phase chromatography (C-18, elution with water/methanol mixtures)
 14. The β/α ratio is very sensitive to the substrate used and the experimental conditions, and some selectivity in favor of the β anomer can be achieved. We are currently looking for conditions that will maximize this ratio.
 15. Dideoxycytidine so obtained had $^1\text{H-NMR}$, m.p. and optical rotation in agreement with literature values. See ref. 5a.
 16. Assignment was made on the basis of the $^1\text{H-NMR}$ and UV spectra. Also treatment of isolated 11 with acids gave in variable yield isomerization to the N-9 alkylated compounds 9 and 10. For a precedent, see: M. Miyaki, S. Shimizu Chem.Pharm.Bull., 1970, 18, 732.
 17. A.Bloch, M.J. Robins, J.R. McCarthy J.Med.Chem., 1967, 10, 908.
 18. Dideoxyadenosine had $[\alpha]_D^{23} -25.3^\circ$ (C 1.00, H_2O); lit.¹⁹: $[\alpha]_D^{25} -25.2^\circ$ (C 1.01, H_2O). Dideoxyinosine had IR (KBr) 1700 cm^{-1} ; UV(H_2O): λ_{max} 240 nm. NMR (CDCl_3 , 360 MHz) anomeric proton at δ 6.185 (dd, J = 6.8; 3.3 Hz); $[\alpha]_D^{23} -28.7^\circ$ (C 1.00, DMF).
 19. M.J. Robins, R.K. Robins J. Am. Chem. Soc., 1964, 86, 3585.

(Received in USA 18 November 1987)